Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations

Abstract

Background: There is currently no disease-modifying treatment available to halt or delay the progression of the disease pathology in dementia. An agreed core set of the best-available and most appropriate outcomes for disease modification would facilitate the design of trials and ensure consistency across disease modification trials, as well as making results comparable and meta-analysable in future trials. Objectives: To agree a set of core outcomes for disease modification trials for mild to moderate dementia with the UK dementia research community and patient and public involvement (PPI). Data sources: We included disease modification trials with quantitative outcomes of efficacy from (1) references from related systematic reviews in workstream 1; (2) searches of the Cochrane Dementia and Cognitive Improvement Group study register, Cochrane Central Register of Controlled Trials, Cumulative Index to Nursing and Allied Health Literature, EMBASE, Latin American and Caribbean Health Sciences Literature and PsycINFO on 11 December 2015, and clinical trial registries [International Standard Randomised Controlled Trial Number (ISRCTN) and clinicaltrials.gov] on 22 and 29 January 2016; and (3) hand-searches of reference lists of relevant systematic reviews from database searches. Review methods: The project consisted of four workstreams. (1) We obtained related core outcome sets and work from co-applicants. (2) We systematically reviewed published and ongoing disease modification trials to identify the outcomes used in different domains. We extracted outcomes used in each trial, recording how many used each outcome and with how many participants. We divided outcomes into the domains measured and searched for validation data. (3) We consulted with PPI participants about recommended outcomes. (4) We presented all the synthesised information at a conference attended by the wider body of National Institute for Health Research (NIHR) dementia researchers to reach consensus on a core set of outcomes. Results: We included 149 papers from the 22,918 papers screened, referring to 125 individual trials. Eighty-one outcomes were used across trials, including 72 scales [31 cognitive, 12 activities of daily living (ADLs), 10 global, 16 neuropsychiatric and three quality of life] and nine biological techniques. We consulted with 18 people for PPI. The conference decided that only cognition and biological markers are core measures of disease modification. Cognition should be measured by the Mini Mental State Examination (MMSE) or the Alzheimer’s Disease Assessment Scale – Cognitive subscale (ADAS-Cog), and brain changes through structural magnetic resonance imaging (MRI) in a subset of participants. All other domains are important but not core. We recommend using the Neuropsychiatric Inventory for neuropsychiatric symptoms: the Disability Assessment for Dementia for ADLs, the Dementia Quality of Life Measure for quality of life and the Clinical Dementia Rating scale to measure dementia globally. Limitations: Most of the trials inclu...

Maintaining cognitive function with internet use: a two-country, six-year longitudinal study

“…In particular, specific internet activities could be addressed. Also, more specific cognitive outcomes could be examined, such as information processing speed, cognitive flexibility, and magnetic resonance imaging (Slegers et al, 2009;Webster et al, 2017), and more pertinent confounders could be added, such as vision impairment and personality (Gell et al, 2015;Berner et al, 2017). If replicated, our findings may warrant well-designed intervention studies (Klimova, 2016;Yates et al, 2016).…”

Aerobic and strength training exercise programme for cognitive impairment in people with mild to moderate dementia: the DAPA RCT

“…Cognitive deficits are central to dementia and widely understood as the most important treatment target. 77 The ADAS-Cog was collected directly from the participant, takes about 30-40 minutes to administer and has established sensitivity to change. It is widely considered the gold standard primary outcome in treatment trials for dementia, with relatively well-established treatment effect sizes.…”

Determinants of self‐ and carer‐rated quality of life and caregiver burden in Alzheimer disease

“…3 Validated assessment scales to measure QoL in dementia exist, and the importance of QoL appraisals is generally acknowledged both in clinical routine and research settings. 4,5 Effective strategies to maintain QoL in individuals affected by dementia can only be devised if the underlying factors are understood.…”